Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements
Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company developing RNAi therapies for KRAS-driven cancers, has regained compliance with Nasdaq's listing requirements. The company has met both the minimum bid price requirement of $1.00 per share and the minimum shareholders' equity requirement of $2.5 million.
The company is preparing for Phase 2/3 clinical trials of its SIL204 therapy, scheduled for the first half of 2026. Recent preclinical data showed promising results with up to 97% inhibition rates across multiple KRAS-driven cancer types. Silexion has also established a strategic CRO collaboration to advance its clinical development strategy.
Silexion Therapeutics (NASDAQ: SLXN), una azienda biofarmaceutica in fase clinica che sviluppa terapie RNAi per tumori guidati da KRAS, ha riconquistato la conformità ai requisiti di quotazione della Nasdaq. L'azienda ha soddisfatto sia il requisito di prezzo minimo per azione di 1,00 dollari sia il requisito di capitale sociale minimo di 2,5 milioni di dollari.
L'azienda si sta preparando per i protocolli di studi clinici di fase 2/3 della terapia SIL204, previsti per la prima metà del 2026. Dati preclinici recenti hanno mostrato risultati promettenti con tassi di inibizione fino al 97% in diversi tipi di tumore guidati da KRAS. Silexion ha inoltre stipulato una collaborazione strategica con un CRO per avanzare la sua strategia di sviluppo clinico.
Silexion Therapeutics (NASDAQ: SLXN), una empresa biofarmacéutica en etapa clínica que desarrolla terapias RNAi para cánceres impulsados por KRAS, ha vuelto a cumplir con los requisitos de cotización de Nasdaq. La empresa ha cumplido tanto el requisito de precio mínimo de oferta de 1,00 USD por acción como el requisito de patrimonio neto mínimo de 2,5 millones de USD.
La compañía se está preparando para ensayos clínicos de fase 2/3 de su terapia SIL204, previstos para la primera mitad de 2026. Datos preclínicos recientes mostraron resultados prometedores con tasas de inhibición de hasta el 97% en varios tipos de cáncer impulsados por KRAS. Silexion también ha establecido una colaboración estratégica con una CRO para avanzar en su estrategia de desarrollo clínico.
Silexion Therapeutics (NASDAQ: SLXN), KRAS 주도 암에 대한 RNAi 치료제를 개발하는 임상단계 바이오제약 회사는 나스닥의 상장 요건을 다시 충족했습니다. 주당 1.00달러의 최소 호가 요건과 최소 주주 지분 요건 250만 달러를 모두 충족했습니다.
회사은 SIL204 치료제의 2상/3상 임상시험을 준비 중이며, 2026년 상반기에 예정되어 있습니다. 최근의 전임상 데이터는 다수의 KRAS 주도 암 유형에서 최대 97%의 억제율로 유망한 결과를 보였습니다. Silexion은 또한 임상 개발 전략을 추진하기 위한 전략적 CRO 협력을 수립했습니다.
Silexion Therapeutics (NASDAQ : SLXN), une société de biotechnologie en phase clinique qui développe des thérapies RNAi pour les cancers causés par KRAS, a retrouvé sa conformité avec les exigences d'inscription au Nasdaq. La société a satisfait à la fois à l'exigence de cours minimal par action de 1,00 USD et à l'exigence de fonds propres des actionnaires minimale de 2,5 millions de dollars.
La société se prépare à des essais cliniques de phase 2/3 de sa thérapie SIL204, prévus pour le premier semestre 2026. Des données précliniques récentes ont montré des résultats prometteurs avec des taux d'inhibition allant jusqu'à 97 % dans plusieurs cancers KRAS-dépendants. Silexion a également établi une collaboration stratégique avec une CRO pour faire progresser sa stratégie de développement clinique.
Silexion Therapeutics (NASDAQ: SLXN), ein klinisches Biotech-Unternehmen, das RNAi-Therapien für KRAS-gesteuerte Krebsarten entwickelt, hat die Compliance mit den Nasdaq-Listing-Anforderungen wiederhergestellt. Das Unternehmen hat sowohl die Mindestanforderung des Mindestkurswerts von 1,00 USD pro Aktie als auch die Mindestkapitalanforderung der Aktionäre von 2,5 Millionen USD erfüllt.
Das Unternehmen bereitet sich auf Phase-2/3-Studien seiner SIL204-Therapie vor, die für das erste Halbjahr 2026 terminiert sind. Jüngste präklinische Daten zeigten vielversprechende Ergebnisse mit bis zu 97% Hemmungsraten bei mehreren KRAS-gesteuerten Krebsarten. Silexion hat außerdem eine strategische CRO-Kollaboration etabliert, um seine klinische Entwicklungsstrategie voranzutreiben.
Silexion Therapeutics (NASDAQ: SLXN)، شركة تكنولوجيا حيوية في مرحلة سريرية تطور علاجات RNAi لسرطانات KRAS، استوفت الامتثال لمتطلبات إدراج ناسداك مجدداً. لقد وفّرت الشركة كل من متطلب الحد الأدنى لسعر العرض البالغ 1.00 دولار للسهم و متطلب حقوق المساهمين الدنيا البالغ 2.5 مليون دولار.
تستعد الشركة للمرحلة 2/3 من تجاربها السريرية لعلاج SIL204، المقررة في النصف الأول من 2026. أظهرت بيانات قبل السريرية الأخيرة نتائج واعدة بمعدلات تثبيط تصل إلى 97% عبر أنواع متعددة من سرطانات KRAS. كما أن Silexion أقامت تعاوناً استراتيجياً مع CRO لدفع استراتيجية التطوير السريري لديها.
Silexion Therapeutics（纳斯达克股票代码：SLXN），一家处于临床阶段的生物科技公司，开发针对 KRAS 驱动的癌症的 RNAi 疗法，已重新符合纳斯达克的上市要求。公司已同时满足每股最低报价1.00美元的要求和股东权益最低200万美元的要求。
公司正在为其 SIL204 疗法的2/3期临床试验做准备，计划在2026年上半年进行。最近的前临床数据在多种 KRAS 驱动的癌种中显示出高达97%的抑制率，前景乐观。Silexion 还与 CRO 建立了战略合作关系，以推进其临床开发策略。
- Regained compliance with Nasdaq listing requirements, maintaining market visibility and investor access
- Preclinical data showed strong 97% inhibition rates across multiple cancer types
- Strategic CRO collaboration established for clinical development
- Phase 2/3 clinical trials for SIL204 planned for H1 2026
- Previous non-compliance with listing requirements indicates recent financial challenges
- Phase 2/3 trials not starting until H1 2026, suggesting extended timeline to market
Company Successfully Meets Both Minimum Bid Price and Shareholders' Equity Requirements, Securing Continued Listing on the Nasdaq Capital Market
GRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with both Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), concerning the minimum bid price and shareholders' equity requirements.
The letter, dated September 23, 2025, confirmed that the Company has successfully met the minimum bid price requirement of
"We are pleased to have regained full compliance with Nasdaq's listing requirements," said Ilan Hadar, Chairman and CEO of Silexion Therapeutics. "This milestone reinforces our strong financial foundation as we advance toward our planned Phase 2/3 clinical trials for SIL204 in the first half of 2026. With our recent preclinical data demonstrating up to
About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit: https://silexion.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding Silexion's business strategy, clinical development plans, timeline for Phase 2/3 trials, and expectations regarding SIL204's therapeutic potential, are forward-looking statements. These forward-looking statements are generally identified by terminology such as "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion's ability to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (vi) Silexion's ability to maintain its Nasdaq listing; and (vii) other risks and uncertainties set forth in the documents filed or to be filed with the SEC by the Company, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission on March 18, 2025. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.
Company Contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Capital Markets & IR Contact:
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com
FAQ
Why did Silexion Therapeutics (SLXN) regain Nasdaq compliance in September 2025?
What are the key clinical developments for Silexion Therapeutics (SLXN)?
What type of therapy is Silexion Therapeutics (SLXN) developing?
When will Silexion Therapeutics (SLXN) begin its Phase 2/3 trials for SIL204?
